INTRODUCTION

Agalsidase alfa (brand name Replagal) is a recombinant formulation of human a-galactosidase A (AGAL) which is produced in a human cell line by genetic engineering technology. Agalsidase alfa has been approved for the treatment of Anderson-Fabry disease (AFD) which is an X-linked storage disorder that is caused by a deficiency of the lysosomal enzyme AGAL and the resultant accumulation of globotriaosylceramide [Gb3 or GL-3, also known as ceramidetrihexoside (CTH)] in several tissue types.

This plasmid is designed for expressing Abaloparatide in mammalian cells such as HEK293 or Chinese hamster ovary (CHO) cell.

PRODUCT INFORMATION

Item No.: PPBD-11
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options for promoter and antibiotic selection marker, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Agalsidase-alfa
Brand Names: Replagal
Classification: Recombinant Enzyme
Amino Acid Sequence: Identical to DB15874

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

Germain DP, Elliott PM, Falissard B, et al. The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts. Mol Genet Metab Rep. 2019;19:100454. Published 2019 Feb 6. doi:10.1016/j.ymgmr.2019.100454

Contact Us